Global Information
회사소개 | 문의

심방세동 : 파이프라인 리뷰

Atrial Fibrillation - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 232800
페이지 정보 영문 92 Pages
가격
US $ 2,000 ₩ 2,296,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,592,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,888,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심방세동 : 파이프라인 리뷰 Atrial Fibrillation - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 92 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

심방세동은 심박수가 불규칙해지는(또는 때때로 빨라지는) 질환으로, 인체 내부의 혈류를 정체시키는 원인이 되고 있습니다. 주요 증상은 혈압 저하와 탈진감, 가벼운 두통, 의식 혼탁, 흉통 등입니다. 질병 소인에는 연령, 심장병, 고혈압, 가족력, 음주 등이 있습니다. 약물 치료와 외과적 수술 등이 주요 치료법입니다.

세계 각국에서의 심방세동(Atrial Fibrillation) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

심방세동 개요

치료제 개발

  • 심방세동용 파이프라인 제품 : 개요
  • 심방세동용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 심방세동 치료제

대학/연구기관에서 연구중인 심방세동 치료제

심방세동 치료제 : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

심방세동 치료제 : 개발중인 제품 목록(기업별)

심방세동 치료제 : 연구중인 제품 목록(대학/연구기관별)

심방세동 치료제 개발에 참여하고 있는 기업

  • ARCA biopharma, Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • Cardiome Pharma Corp.
  • Daiichi Sankyo Company, Limited
  • Dong-A Socio Holdings Co. Ltd.
  • Gilead Sciences, Inc.
  • Laboratoires Pierre Fabre SA
  • Nissan Chemical Industries, Ltd.
  • OMEICOS Therapeutics GmbH
  • Otsuka Holdings Co., Ltd.
  • Xention Limited

심방세동 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

약제 개요

심방세동 치료제 : 개발이 휴지 상태인 제품

심방세동 치료제 : 개발이 중지된 제품

심방세동 관련 제품 개발 마일스톤

  • 주목해야 할 최신 동향 및 프레스 릴리스

부록

도표

KSM 16.09.23

List of Tables

  • Number of Products under Development for Atrial Fibrillation, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2018
  • Atrial Fibrillation - Pipeline by AnaBios Corp, H2 2018
  • Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2018
  • Atrial Fibrillation - Pipeline by Boston Pharmaceuticals Inc, H2 2018
  • Atrial Fibrillation - Pipeline by Correvio Pharma Corp, H2 2018
  • Atrial Fibrillation - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2018
  • Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H2 2018
  • Atrial Fibrillation - Pipeline by HUYA Bioscience International LLC, H2 2018
  • Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H2 2018
  • Atrial Fibrillation - Pipeline by Merck & Co Inc, H2 2018
  • Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H2 2018
  • Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H2 2018
  • Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2018
  • Atrial Fibrillation - Pipeline by The Geneva Biotech Center SA, H2 2018
  • Atrial Fibrillation - Dormant Projects, H2 2018
  • Atrial Fibrillation - Dormant Projects, H2 2018 (Contd..1), H2 2018
  • Atrial Fibrillation - Dormant Projects, H2 2018 (Contd..2), H2 2018
  • Atrial Fibrillation - Discontinued Products, H2 2018
  • Atrial Fibrillation - Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

  • Number of Products under Development for Atrial Fibrillation, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2018, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, light headedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular)

List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide

List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 The guide covers therapeutics under Development by Companies /Universities /Institutes,

List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

List of TablesNumber of Products under Development for Atrial Fibrillation, H2 2018 9Number of Products under Development by Companies, H2 2018 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atrial Fibrillation - Overview
    • Atrial Fibrillation - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Atrial Fibrillation - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Atrial Fibrillation - Companies Involved in Therapeutics Development
    • Acesion Pharma Aps
    • AnaBios Corp
    • ARCA biopharma Inc
    • Boston Pharmaceuticals Inc
    • Correvio Pharma Corp
    • Daiichi Sankyo Co Ltd
    • Dong-A Socio Holdings Co Ltd
    • Gilead Sciences Inc
    • HUYA Bioscience International LLC
    • InCarda Therapeutics Inc
    • Merck & Co Inc
    • N-Gene Research Laboratories Inc
    • Nissan Chemical Industries Ltd
    • OMEICOS Therapeutics GmbH
    • The Geneva Biotech Center SA
  • Atrial Fibrillation - Drug Profiles
    • AFC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-30663 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGP-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BOS-1728515 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bucindolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budiodarone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • edoxaban tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flecainide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBCA-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GS-967 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HBI-3000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Heparin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-1832 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NIP-151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMT-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit LGALS3 for Cardiovascular and Genito Urinary System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vernakalant hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Atrial Fibrillation - Dormant Projects
  • Atrial Fibrillation - Discontinued Products
  • Atrial Fibrillation - Product Development Milestones
    • Featured News & Press Releases
      • Jul 17, 2018: OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation
      • Jun 11, 2018: Correvio Provides U.S. Regulatory Update for BRINAVESS
      • May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Hemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organization Conference 2018
      • May 17, 2018: Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess in China
      • Apr 27, 2018: Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics
      • Apr 17, 2018: Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess
      • Mar 12, 2018: Acesion Pharma Commences Phase 1 Study in Atrial Fibrillation
      • Feb 08, 2018: Acesion Pharma Receives Approval for Phase I Study in Atrial Fibrillation
      • Dec 12, 2017: Espero BioPharma Provides Update on Budiodarone
      • Nov 15, 2017: New LIXIANA sub-analysis from the ENGAGE AF-TIMI 48 trial presented at the American Heart Association Annual Scientific Sessions 2017
      • Nov 13, 2017: OMEICOS Announces Formation of Inaugural Clinical Advisory Board
      • Nov 08, 2017: Daiichi Sankyo Announces New Analyses of Once-Daily SAVAYSA (edoxaban) to be Presented at the 2017 American Heart Association Scientific Sessions
      • Nov 02, 2017: Cardiome Announces Expansion of Global Geographic Footprint for Brinavess
      • Oct 06, 2017: Daiichi Sankyo to Install Call Center Support System in Japan Utilizing Artificial Intelligence
      • Sep 14, 2017: G3 Pharmaceuticals to Pursue a Novel Class of Cardiovascular Pharmaceuticals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research